204 related articles for article (PubMed ID: 37955792)
1. Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors.
Lee D; Li M; Liu D; Baumhover NJ; Sagastume EA; Marks BM; Rastogi P; Pigge FC; Menda Y; Johnson FL; Schultz MK
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1147-1162. PubMed ID: 37955792
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for
Li M; Baumhover NJ; Liu D; Cagle BS; Boschetti F; Paulin G; Lee D; Dai Z; Obot ER; Marks BM; Okeil I; Sagastume EA; Gabr M; Pigge FC; Johnson FL; Schultz MK
Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839736
[No Abstract] [Full Text] [Related]
3. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
4. Targeted
Delpassand ES; Tworowska I; Esfandiari R; Torgue J; Hurt J; Shafie A; Núñez R
J Nucl Med; 2022 Sep; 63(9):1326-1333. PubMed ID: 34992153
[TBL] [Abstract][Full Text] [Related]
5. Radiopharmaceuticals used for diagnosis and therapy of NETs.
Papachristou M
Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
[TBL] [Abstract][Full Text] [Related]
6.
King AP; Gutsche NT; Raju N; Fayn S; Baidoo KE; Bell MM; Olkowski CS; Swenson RE; Lin FI; Sadowski SM; Adler SS; Thiele NA; Wilson JJ; Choyke PL; Escorcia FE
J Nucl Med; 2023 Apr; 64(4):549-554. PubMed ID: 36396453
[TBL] [Abstract][Full Text] [Related]
7. Peptide Receptor Radionuclide Therapy with
Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
[TBL] [Abstract][Full Text] [Related]
8. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of [
Njotu FN; Ketchemen JP; Tikum AF; Babeker H; Gray BD; Pak KY; Uppalapati M; Fonge H
J Nucl Med; 2024 Apr; 65(4):533-539. PubMed ID: 38485273
[TBL] [Abstract][Full Text] [Related]
10. Multimodal Imaging of 2-Cycle PRRT with
Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ
J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
12.
Gao F; Zhang Y; Chen M; Song Z; Dong R; Qiu S; Shen C; Huang X; Geng H; Cheng W; Hu J
Eur J Pharm Sci; 2024 Feb; 193():106671. PubMed ID: 38104907
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.
Miederer M; Henriksen G; Alke A; Mossbrugger I; Quintanilla-Martinez L; Senekowitsch-Schmidtke R; Essler M
Clin Cancer Res; 2008 Jun; 14(11):3555-61. PubMed ID: 18519789
[TBL] [Abstract][Full Text] [Related]
14. Design, preparation and biological evaluation of a
Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D
Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215
[TBL] [Abstract][Full Text] [Related]
15. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.
Eisenwiener KP; Prata MI; Buschmann I; Zhang HW; Santos AC; Wenger S; Reubi JC; Mäcke HR
Bioconjug Chem; 2002; 13(3):530-41. PubMed ID: 12009943
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
Kaltsas GA; Papadogias D; Makras P; Grossman AB
Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
[TBL] [Abstract][Full Text] [Related]
17. Influence of the Molar Activity of
Pretze M; Michler E; Runge R; Wetzig K; Tietze K; Brandt F; Schultz MK; Kotzerke J
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004470
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
20. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors.
Giovacchini G; Nicolas G; Forrer F
Anticancer Agents Med Chem; 2012 Jun; 12(5):526-42. PubMed ID: 22292758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]